Biotech Sector Faces Headwinds Amid Sparse News Flow and Regulatory Uncertainty

Eli Lilly's $7 Billion Acquisition of Kelonia Therapeutics Signals Shift to In Vivo CAR-T in Oncology

Southern Florida's Biotech Surge: Transforming the U.S. Life Sciences Landscape Amid Capital and Talent Inflows

Sanofi's Q1 Surge and New CEO Transition Signal Biotech Resilience Amid Pipeline Shifts

Roche's Gazyva Advances in Lupus Treatment as FDA Accepts Supplemental Application

Trump's Psychedelics Executive Order Ignites Biotech Rally as FDA Fast-Track Accelerates Mental Health Drug Development

Flagship Pioneering Launches Serif Biomedicines with $50M to Pioneer Modified DNA Therapeutics

Novo Nordisk's Etavopivat Phase 3 Triumph Signals New Era for Sickle Cell Disease Treatments

Eli Lilly's $7B Kelonia Acquisition Signals Aggressive Pivot to In Vivo CAR-T Manufacturing Revolution

Strait of Hormuz Reopening Catalyzes Biotech Rally as Energy Cost Relief Boosts Sector Margins

Moderna's mRNA-4359 Receives FDA Fast Track for Melanoma, Driving 5.4% Stock Surge Amid Oncology Pivot

Breakthrough Prize Validates Gene Therapy Milestone, Boosting Biotech Innovation Pipeline

CRISPR Safety Review Signals Regulatory Hurdles for Gene Editing Biotech Pipelines

Danaher, United Therapeutics, and Vertex Lead Biotech Surge: Implications for Pipelines and Stocks

Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial, Secures $2B Funding Boost

FDA Greenlights exa-cel: CRISPR Milestone Reshapes Biotech Landscape for Vertex and Beyond

Cochrane Review Challenges Anti-Amyloid Alzheimer's Drugs, Pressuring Biotech Valuations and Pipelines

BIO's 'The Fight of Our Lives' Campaign Signals Biotech's Push for Sustained Investment Amid Funding Pressures

FDA Fast Track for Opna Bio's OPN-6602 Signals Momentum in Multiple Myeloma Innovation

BIOTRONIK's Solia CSP S FDA Approval Ushers in New Era for Cardiac Pacing Innovation

Vertex Pharmaceuticals Leads Biotech Rally as Covered Call Strategies Reshape Institutional Positioning

GSK Accelerates B7-H4 ADC Mo-Rez to Five Phase 3 Trials on Strong Phase 1 Data in Ovarian and Endometrial Cancers

Revolution Medicines' Daraxonrasib Delivers Breakthrough Phase 3 Data in Pancreatic Cancer, Shares Surge 40%

Bluebird Bio's Lyfgenia Delivers First Sickle Cell Cure, Signaling Gene Therapy's Commercial Breakthrough

ImmunityBio's 168% Revenue Surge Signals Anktiva Momentum as Biotech Sector Eyes Immunotherapy Validation

FDA's Second Rejection of Replimune's RP1 Triggers Biotech Stock Selloff and Raises Trial Design Scrutiny

No Verified Biotech Breakthroughs in Last 24 Hours: Sector Holds Steady Amid Macro Pressures

DNLI Surges on FDA Approval of Avlayah for Hunter Syndrome: Biotech Milestone Signals Regulatory Tailwinds

OpenAI's $100M Alzheimer's AI Grants Ignite Biotech Investment Boom and Accelerate Drug Pipelines

FDA Fast Track for NextCure's SIM0505 Signals Momentum in Ovarian Cancer ADC Space

Gilead's $3.15B Tubulis Acquisition Bolsters ADC Dominance in Oncology Pipeline

Gilead's $3B+ Acquisition of Tubulis Bolsters ADC Leadership in Oncology Pipeline

Artivion's FDA Approval of NEXUS Aortic Arch System Unlocks New Era in Endovascular Aortic Treatments

Neurocrine Biosciences' $2.9B Soleno Acquisition Signals Biotech Consolidation in Rare Disease Space

FDA Delays Force Biotech Crunch: Kezar Closes Doors Amid Regulatory Hurdles

Vertex Pharmaceuticals' CF Expansions and IgAN Filing Signal Biotech Pipeline Diversification Amid Regulatory Momentum

Promising First-in-Human CRISPR/Cas12a Data for Sickle Cell Therapy Signals Biotech Pipeline Acceleration

GLP-1 Market Explosion Reshapes Biotech Investment Landscape as Digital Health Funding Surges

CRISPR Therapeutics Stock Gains Momentum Post-Earnings on Expanding Pipeline Prospects

Allevion Medical's FDA Clearance for Vantage System Signals Innovation Wave in Spinal Decompression Medtech

FDA's Evolving Breakthrough Device Standards Signal Shift in AI-Driven Cancer Detection Approvals

Eli Lilly's $7.8B Centessa Acquisition Signals Biotech M&A Resurgence and Neuroscience Push

Eli Lilly's Foundayo Reshapes Obesity Market as GLP-1 Oral Competition Intensifies

FORE Biotherapeutics Achieves Historic FDA Breakthrough Designation for Plixorafenib in High-Grade Glioma

VDYNE's FDA IDE Approval Signals Momentum in Tricuspid Valve Innovation Amid Biotech Regulatory Tailwinds

ADC Platform Innovation Reshapes Oncology Pipeline as HER2, TROP2 Dominate AACR 2026

Praxis Precision Medicines Advances Relutrigine to FDA Priority Review, Targeting First-in-Class Rare Epilepsy Therapy

GLP-1 Receptor Agonist Market Heats Up with BioNxt Semaglutide Advance, Novo FDA Nod and Generic Onslaught

Eli Lilly's $2.75B AI Pact with Insilico Signals Biotech's AI Revolution

Pfizer-Valneva's Mixed Lyme Vaccine Data Signals Biotech Resilience Amid Phase III Hurdles

FDA Accelerated Approval of Rocket Pharma's Kresladi Marks Milestone for Gene Therapy in Rare Pediatric Diseases

FDA Greenlights Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin Reshapes Diabetes Treatment Landscape

Novartis' $2B Excellergy Acquisition Signals Big Pharma's Aggressive Push into Next-Gen Allergy Therapies

Merck's $6.7B Terns Acquisition Bolsters Oncology Pipeline Amid Keytruda Cliff

Insilico Medicine Expands AI-Driven CNS Collaboration with Tenacia, Unlocking Up to $94.75M in Milestones

Merck's $6.7 Billion Acquisition of Terns Signals Biotech M&A Resurgence Amid Keytruda Patent Cliff

Merck's $6.7 Billion Terns Acquisition Signals Aggressive Pipeline Diversification Amid Keytruda Patent Cliff

Gilead's $3.4B Ouro Medicines Acquisition Signals Biotech M&A Revival in Autoimmune Space

Siren Biotechnology's FDA IND Clearance Signals Gene Therapy Momentum in Oncology

Echo IQ Shares Surge 14% on Enhanced Mayo Clinic Deal Amid FDA Path for Heart Failure AI Tool

Vanda Pharmaceuticals Plunges 17.63% as CEO's Major Stock Sale Sparks Investor Alarm Amid Regulatory Setbacks

Biotech IPO Market Shows Early Signs of Reopening After Multi-Year Drought in 2026

Amneal Pharmaceuticals Signals Margin Expansion with 2026 Guidance Amid Biosimilars Push

MarketBeat Flags Top Biotech Stocks Driving Volume: Danaher, Moderna, Vertex Lead High-Risk Surge

Immunocore's Five-Year Survival Data for KIMMTRAK at AACR Signals Long-Term Efficacy Milestone in Oncology

BioNTech Leadership Exodus Triggers 18% Stock Plunge Amid Weak 2026 Guidance

Therma Bright Grants 2.85M Stock Options Amid Biotech Diagnostic Push

Immutep Shares Plunge 93% as Phase III Cancer Trial Halted on Futility Analysis

Merck's Keytruda Wins FDA Approval for New Gastric Cancer Indication, Boosting Oncology Pipeline

Pfizer's High-Stakes Pivot to Oncology and Obesity: A 2026 Turning Point for Biotech Investors

Telix Pharmaceuticals' ProstACT Global Phase 3 Milestone Ignites Biotech Momentum in Prostate Cancer Treatment

Dianthus Therapeutics Gears Up for Pivotal Phase 3 Interim Data Reveal in CIDP, Stock Poised for Momentum

Iovance Biotherapeutics Emerges as Top Biotech Watch Amid Surging Trading Volume and Melanoma Therapy Momentum

Novo Nordisk Receives FDA Breakthrough Designation for GLP-1 Combination Therapy in Obesity Management

Merck's Keytruda Wins FDA Approval for New Cancer Indication, Boosting Biotech Momentum

Novo Nordisk Faces Patent Challenge as GLP-1 Competitor Gains FDA Momentum

Vertex Pharmaceuticals Q4 Earnings Beat Signals Biotech Powerhouse Expansion Beyond CF

Syndax Pharmaceuticals Achieves Third FDA Approval in 12 Months, Pivots to Multi-Product Revenue Model

Generate Biomedicines' $400M IPO Signals Renewed Investor Appetite for AI-Driven Drug Discovery

Generate Biomedicines Raises $400M in Blockbuster IPO, Signaling Biotech Revival Amid AI Drug Discovery Boom

Torrent Pharmaceuticals Hits All-Time High: 606% Decade-Long Surge Signals Biotech Resilience Amid Sector Volatility

Raymond James Upgrades Vir Biotechnology to Strong Buy on Promising Drug Data, Signaling Biotech Momentum

Moderna (MRNA) Advances mRNA Vaccine Pipeline Beyond COVID-19

Biogen (BIIB) Gains FDA Approval for New Alzheimer's Drug